<DOC>
	<DOCNO>NCT00143546</DOCNO>
	<brief_summary>Veno-occlusive disease ( VOD ) liver significant complication patient undergoing hematopoietic stem cell transplantation . This disease think toxicity secondary chemotherapy radiation-induced damage epithelial cell blood vessel liver . VOD categorize mild , moderate severe . Historically , method treat disease . Recently , however , investigation use new agent call defibrotide . The primary purpose protocol provide defibrotide patient severe VOD . Because drug approve FDA , use medication auspex IND treatment plan compassionate use .</brief_summary>
	<brief_title>Compassionate Use Defibrotide Patients With Veno-occlusive Disease Liver</brief_title>
	<detailed_description>Secondary objective protocol include follow : - To describe toxicity defibrotide patient VOD . - To describe response rate VOD patient receive defibrotide .</detailed_description>
	<mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Patients clinical pathologic diagnosis venoocclusive disease . The following criterion use : 1 . Hyperbilirubinemia ( great equal 2mg/dl ) two follow : ( hepatomegaly , ascites , weight gain [ great equal 5 % baseline ] ) ; OR , 2 . Patient fulfill criterion # 1 pathologic radiographic evidence VOD .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hepatic Veno-occlusive Disease</keyword>
</DOC>